Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable ...

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation therapy.

Men suffering from the disruptive symptoms of an enlarged prostate now have a new treatment option available at East Georgia Regional Medical Center. The hospital has introduced a state-of-the-art, ...

Leg-spinner Yuzvendra Chahal's maiden six-wicket for India as the hosts beat England by 75 runs in the third and final Twenty20 International ...

Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...